Novartis Launches Virtual Innovation Hub to Accelerate Digital Health Solutions in Sub-Saharan Africa
Novartis has announced the launch of its new innovation hub, Novartis Biome sub-Saharan Africa (SSA), which will spearhead the further development of innovative business models and technology-driven solutions to improve healthcare in the region. The hub will focus on cross-sectoral partnerships to accelerate innovative approaches to increase affordable access to high-quality medicines and sustainably strengthen health systems.
“Our goal is to provide every patient in SSA with affordable access to high-quality medicines and to ultimately transform healthcare in the region. For this, innovation and digital technologies have an immense potential to contribute, and with cross-sectoral partnerships, we can truly maximize the impact on the health of our people,” said Racey Muchilwa, President and Head, Novartis Sub-Saharan Africa.
Recognizing that access to medicines remains one of the world’s biggest healthcare challenges, and with Africa being home to the largest underserved population in the world, the Novartis Biome SSA will concentrate on four strategic priorities:
1) extend affordability of healthcare
2) strengthen early diagnosis to drive better outcomes
3) lead in supply chain innovation
4) support HCP education and patient awareness
Working across these four priorities supports Novartis aspiration to double its patient reach in Sub-Saharan Africa by 2022 and increase it five-fold by 2025.
“While healthcare innovation is at the core of our work at Novartis, we know that no single company can solve these challenges alone. Building strong partnerships and fostering greater collaboration is the only way to truly drive transformative, meaningful access improvements in our region,” continued Muchilwa.
People In This Post
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more